TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12374512
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with antihypertensive therapy (nitrendipine 10-40 mg/d, possibly with enalapril maleate 5-20 mg/d and/or hydrochlorothiazide 12.5-25 mg/d)
Study: 12374512
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with antihypertensive therapy
Study: 30499618
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 plus Calcium (1200 mg daily)
Study: 28333510
Drug: ADHD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD treatment (medication + parent training)
Study: 28333510
Drug: Reading treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading treatment (reading instruction)
Study: 28333510
Drug: Combined ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ADHD + reading treatment
Study: 25092686
Drug: β-adrenergic antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: β-adrenergic antagonist propranolol
Study: 21779819
Drug: Bazedoxifene 40/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 40/20 mg
Study: 21779819
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 mg (higher-risk subgroup)
Study: 21779819
Drug: Bazedoxifene 20
Normalized name: bazedoxifene 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 20 and 40/20 mg (combined data)
Study: 19171224
Drug: Platelet-inhibitory doses
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-inhibitory doses of aspirin (maximal total dose: 400mg/day)
Study: 15826746
Drug: Neridronate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (25 mg intramuscular monthly)
Study: 15826746
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and cholecalciferol (500 mg of elemental calcium and 400 IU cholecalciferol daily)
Study: 15826746
Drug: Neridronate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (25 mg intramuscular monthly) with calcium and cholecalciferol
Study: 8199810
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 60 mg/kg infused intravenously
Study: 31900166
Drug: Caffeine supplementation
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine supplementation (6 mg/kg)
Study: 20620788
Drug: Hamstring donor-site
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamstring donor-site block (20-mL injection of 0.25% bupivacaine)
Study: 20620788
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no hamstring donor-site block)
Study: 16115337
Drug: VPP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPP and IPP 1.8 mg
Study: 16115337
Drug: VPP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPP and IPP 2.5 mg
Study: 16115337
Drug: VPP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPP and IPP 3.6 mg
Study: 15544888
Drug: Metronidazole 1600
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole 1600 mg
Study: 11060718
Drug: Oestrogen replacement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen replacement, anti-inflammatory agents, free radical scavengers, anti-oxidants, MAO-B inhibitors
Study: 3896455
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with vincristin (1.2 mg/m2), Adriamycin (40 mg/m2), cyclophosphamide (500 mg/m2), and medroxyprogesteron acetate (MPA) (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Study: 3896455
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with the same combination chemotherapy (VAC) for three cycles alternating with MPA (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Study: 3896455
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy
Study: 2905566
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg/kg + atropine 0.01 mg/kg
Study: 2905566
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg/kg
Study: 2905566
Drug: d-tubocurarine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-tubocurarine 0.5 mg/kg
Study: 2905566
Drug: alcuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcuronium 0.3 mg/kg
Study: 2905566
Drug: pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium 0.1 mg/kg
Study: 2905566
Drug: atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: atracurium 0.5 mg/kg
Study: 27784211
Drug: FDSFs (Fast
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDSFs (Fast Dissolving Sublingual Films) containing Pullulan with Maltodextrin in a ratio 3:1
Study: 27784211
Drug: FDSFs (Fast
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDSFs (Fast Dissolving Sublingual Films)
Study: 27784211
Drug: Ventolin® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin® tablets 2 mg
Study: 21572327
Drug: Initial antibiotics
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotics administered before shock recognition
Study: 21572327
Drug: Initial antibiotics
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotics administered after shock recognition
Study: 21572327
Drug: Hourly delays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hourly delays in antibiotic administration after shock recognition
Study: 9279722
Drug: PM inactivated
Normalized name: rabies virus vaccine wistar strain PM-1503-3M (human), inactivated Injection [Imovax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM inactivated hepatitis A vaccine
Study: 9279722
Drug: SB inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB inactivated hepatitis A vaccine
Study: 29778281
Drug: Water-drinking test
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-drinking test (WDT) in patients on medical treatment for POAG
Study: 29778281
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (two or more medications)
Study: 27351217
Drug: 2L treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2L treatment after 1L nab-P+Gem
Study: 27351217
Drug: 2L treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2L treatment after 1L Gem
Study: 27351217
Drug: 2L therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2L therapy containing fluoropyrimidine after 1L nab-P+Gem
Study: 27351217
Drug: 2L therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2L therapy containing fluoropyrimidine after 1L Gem
Study: 23775961
Drug: Pemetrexed (P)
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed (P) 500 mg/m²
Study: 23775961
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and Pemetrexed (CP) AUC 5 and 500 mg/m²
Study: 18256069
Drug: Infliximab at
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab at 3 and 5 mg/kg body weight administered over 24 weeks
Study: 12942031
Drug: Bilevel therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilevel therapy
Study: 10481861
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with daunorubicin 45 mg/m2 (group 1, trial 2)
Study: 10481861
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with daunorubicin 60 mg/m2 (group 3, trial 2)
Study: 10481861
Drug: Induction with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction with daunorubicin 45 mg/m2 (group 2, trial 2)
Study: 1952845
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of ketoconazole alone
Study: 1952845
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of sucralfate with 400 mg of ketoconazole
Study: 1952845
Drug: Ranitidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administered 2 h prior to 400 mg of ketoconazole
Study: 30169267
Drug: Inactivated quadrivalent
Normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated quadrivalent influenza vaccine (IIV4) - 15 μg haemagglutinin antigen per strain per 0.5 mL dose; single dose on day 0 for vaccine-primed children, and two doses on days 0 and 28 for vaccine-unprimed children.
Study: 30169267
Drug: Non-influenza control
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-influenza control vaccine (one or two doses).
Study: 27221874
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (SQT)
Study: 27221874
Drug: 14-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day standard triple therapy (STT)
Study: 24262967
Drug: Sibutramine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine therapy
Study: 17074778
Drug: Spray disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spray disinfection with 2-propanol and benzalkonium chloride (SP)
Study: 12001325
Drug: Intermittent pneumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent pneumatic compression (IPC) as an adjuvant therapy
Study: 9787885
Drug: Low-dose ECT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ECT
Study: 7897158
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (120 mg, by mouth, daily)
Study: 2698894
Drug: Lidocaine periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine periodontal ligament injections
Study: 2698894
Drug: Epinephrine periodontal
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine periodontal ligament injections
Study: 4802389
Drug: 1000 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 CCA unit Aichi/68 influenza vaccine
Study: 4802389
Drug: 1000 CCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 CCA unit Japan/57 influenza vaccine
Study: 27449500
Drug: Adjunctive peri-operative
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive peri-operative steroid combination (triamcinolone acetonide) 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon's space.
Study: 27449500
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment and routine pre-operative and post-operative treatment and care.
Study: 19833214
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg/d)
Study: 20547795
Drug: Fixed-dose artesunate-mefloquine
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose artesunate-mefloquine (AS-MQ) - 100 mg AS and 200 mg MQ/tablet daily for 3 days (days 0, 1, and 2)
Study: 20547795
Drug: Nonfixed artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nonfixed artesunate plus mefloquine (AS-plus-MQ) - 4 mg/kg AS/day for 3 days plus 15 mg/kg MQ on day 1 and 10 mg/kg on day 2
Study: 20547795
Drug: Fixed-dose AS-MQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose AS-MQ
Study: 18543307
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment in patients with eGFR > 75.0 mL/min/1.73 m² (Group I)
Study: 18543307
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment in patients with eGFR 60.0 to 74.9 mL/min/1.73 m² (Group II)
Study: 18543307
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment in patients with eGFR 45.0 to 59.9 mL/min/1.73 m² (Group III)
Study: 18543307
Drug: ICD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD treatment in patients with eGFR ≤ 45.0 mL/min/1.73 m² (Group IV)
Study: 15878723
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with haloperidol (3‐10 mg/day for 2‐4 months)
Study: 15878723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Normal participants with no experience with antipsychotic drugs)
Study: 12902363
Drug: Cognitive-Behavioral Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Intervention for Trauma in Schools (10-session standardized cognitive-behavioral therapy)
Study: 9581986
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (Ome20)
Study: 9581986
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg (Ome10)
Study: 9581986
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (Ome20) in oesophagitis patients
Study: 9581986
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg (Ome10) in oesophagitis patients
Study: 9581986
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up (6 months off treatment)
Study: 1832753
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment group
Study: 1832753
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment group
Study: 6810013
Drug: Sustak 6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustak 6.4 mg
Study: 28635153
Drug: Silymarin gel
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin gel 1% applied twice daily for 9 weeks
Study: 20947374
Drug: Vorapaxar (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar (1 or 2.5 mg) plus aspirin (75-150 mg/day)
Study: 20947374
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin (75-150 mg/day)
Study: 15316750
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral docetaxel combined with 500 mg OC144‐093
Study: 19509162
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg i.v. docetaxel
Study: 11172188
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of therapy for 12 weeks
Study: 11172188
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of therapy
Study: 2138182
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg/kg single injection, continuous infusion at 5 and 10 micrograms/kg.min)
Study: 23769325
Drug: Improved adherence
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved adherence to medication
Study: 8058420
Drug: Albuterol administered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administered by metered dose inhaler through a spacer device (Babyhaler)
Study: 2221865
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1,000 mg orally) taken 1 hour before a meal (BE)
Study: 2221865
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1,000 mg orally) taken with a meal (WI)
Study: 2221865
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1,000 mg orally) taken 1 hour after a meal (AF)
Study: 2221865
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 250 ml
Study: 2221865
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (1,000 mg orally) under fasted conditions with fluid volume intake of 450 ml
Study: 657082
Drug: Cyclophosphamide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (30 mg/kg total dose) given for one six-day course immediately after mastectomy
Study: 657082
Drug: Cyclophosphamide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (30 mg/kg total dose)
Study: 657082
Drug: Cyclophosphamide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (30 mg/kg total dose) given 3 weeks after mastectomy
Study: 15483784
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (6 g ethyl ester daily for 16 weeks)
Study: 15483784
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil (SO) supplementation (6 g ethyl ester daily for 16 weeks)
Study: 7888537
Drug: Didanosine (buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (buffered powder for oral solution, total daily doses of 6.6‐10 mg/kg)
Study: 3184196
Drug: CVPP (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP (cyclophosphamide, vinblastine, procarbazine, and prednisone) alone for 6 monthly cycles
Study: 3184196
Drug: CVPP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVPP plus RT (radiation therapy, 3,000 rad)
Study: 4880663
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of tetracycline, divided into 4 doses, daily for 5 days
Study: 4880663
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g of tetracycline in a single dose daily for 5 days
Study: 4880663
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1.0 g of tetracycline
Study: 4880663
Drug: Multivitamin preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin preparations
Study: 31200019
Drug: Conventional sample
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sample preparation methods
Study: 21972615
Drug: Moxibustion at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion at Guanyuan (CV 4) and Shenque (CV 8) in addition to standard treatment
Study: 21972615
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment including Mifepristone, Rivanol, Misoprostol, uterine curettage, and Oxytocin
Study: 16738738
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg/day of zinc sulfate for four months)
Study: 15327560
Drug: TriAc (0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TriAc (0.1% in hydrophilic ointment) applied twice daily for 8 weeks
Study: 16428147
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 8 weeks
Study: 8275621
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg candoxatril
Study: 8275621
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg candoxatril
Study: 8275621
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg candoxatril
Study: 28681988
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg/d
Study: 21225314
Drug: Gemcitabine/cisplatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/cisplatin plus 7.5 mg/m² rh-endostatin
Study: 16248237
Drug: Shensong yangxin
Normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shensong yangxin capsule (SYC)
Study: 16248237
Drug: Xinlvning tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinlvning tablet (Control)
Study: 10395121
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of clodronate (400, 800, and 1600 mg) to healthy volunteers
Study: 10395121
Drug: Clodronate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (800 and 1600 mg) twice daily for one week to cancer patients
Study: 10395121
Drug: Routine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy with clodronate (400 mg thrice daily) in hospitalized cancer patients